jueves, 1 de noviembre de 2012

HIV/AIDS Medicines Update

MedlinePlus sent this bulletin at 10/31/2012 01:19 PM EDT New on the MedlinePlus HIV/AIDS Medicines page:

Pre-Exposure Prophylaxis (PrEP)

10/28/2012 08:00 PM EDT

Source: Centers for Disease Control and Prevention

Treatment for HIV

10/28/2012 08:00 PM EDT

Treatment Decisions and HIV - VA National HIV/AIDS Website

Source: Dept. of Veterans Affairs

Pre-Exposure Prophylaxis (PrEP)

What is PrEP?

PrEP is short for Pre-Exposure Prophylaxis. It is a new HIV prevention method in which people who do not have HIV take a daily pill to reduce their risk of becoming infected. When used consistently, PrEP has been shown to be effective in men who have sex with men (MSM) and heterosexually-active men and women. A CDC study is also underway to evaluate whether PrEP is safe and effective in reducing the risk of HIV infection through injection drug use, but those results are not yet available.
Based on studies to date, in July 2012 the U.S. Food and Drug Administration approved the combination medication tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) for use as PrEP among sexually active adults at risk for HIV infection.
For some individuals at high risk for HIV infection, PrEP may represent a much-needed additional prevention method, but it will not be right for everyone and is not intended to be used in isolation, but rather in combination with other methods to reduce the risk of getting HIV infection. If it is delivered effectively and targeted to those at highest risk, PrEP may play a role in helping to reduce the significant continuing toll of new HIV infections in the United States. CDC is currently working with partners to ensure safe and effective PrEP use and begin to address key questions about acceptability, access, adherence, behavioral risks, and patient outcomes in community settings.

Updates

Press Release: CDC issues interim guidance on use of medication to prevent HIV infection among heterosexually-active adults (Added on August 9, 2012)
MMWR: Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually-Active Adults (Added on August 9, 2012)
Media Statement: CDC Statement on FDA Approval of Drug for HIV Prevention (Added on July 16, 2012)
Fact Sheet: Pre-Exposure Prophylaxis for HIV Prevention (Added on August 9, 2012)
Fact Sheet: TDF2 Study of Pre-Exposure Prophylaxis (PrEP) Among Heterosexual Men and Women in Botswana: Key Facts (Added on July 16, 2012)

CDC PrEP Guidance

CDC is leading national efforts to develop comprehensive Public Health Service guidelines for PrEP. Until those more detailed guidelines are available, CDC has developed interim guidance for physicians electing to provide PrEP for HIV prevention among MSM and among heterosexually active women and men.

PrEP Research

In November 2010, the National Institutes of Health (NIH) announced the results of the iPrEx clinical trial, a large, multi-country research study examining PrEP among MSM. The study found that daily oral use of TDF/FTC provided an average of 44% additional protection to MSM who also received a comprehensive package of prevention services that included monthly HIV testing, condom provision, and management of other sexually transmitted infections. The level of protection varied widely depending on how consistently participants used PrEP, with significantly greater levels of protection among those who adhered well to the daily regimen. Among MSM with detectable levels of the medication in their blood, the risk of HIV acquisition was reduced by more than 90 percent.
In July 2011, a CDC study called TDF2, along with a separate trial by the University of Washington (Partners PrEP), provided evidence that a daily oral dose of antiretroviral drugs used to treat HIV infection can reduce HIV acquisition among uninfected adults exposed to the virus through heterosexual sex.
TDF2, conducted in partnership with the Botswana Ministry of Health, found that once-daily TDF/FTC reduced the risk of acquiring HIV infection by 62 percent overall in the study population of uninfected heterosexually-active men and women. Blood level data showed that participants who became infected had far less drug in their blood, compared with matched participants who remained uninfected suggesting that medication adherence is associated with the efficacy of PrEP in preventing HIV infection.
Partners PrEP found that two separate antiretroviral regimens – TDF/FTC in combination and tenofovir alone – when provided to uninfected persons whose partners have HIV infection (serodiscordant couples) significantly reduced HIV acquisition (by 75 percent and 67 percent, respectively). Participants in the TDF/FTC group with detectable levels of the medication experienced a 90 percent reduction in risk for HIV infection; in the tenofovir- only group, the presence of medication in the blood was associated with an 86 percent reduction in risk. CDC co-managed two of the nine sites for this study.